Infinity Pharmaceuticals Rule of 40
The Rule of 40 of Infinity Pharmaceuticals (INFIQ) as of Oct 19, 2026 is -1,689.87 %. In the previous year, Rule of 40 was -2,418.29 % — a change of -30.12% (higher).
Get this data via API
Financial Data API
Rule of 40
-1,689.87 %
YoY
-30.12%
Last updated:
The Infinity Pharmaceuticals Rule of 40 history
3 Years
10 Years
25 Years
Max
| YEAR | Rule of 40 | YoY |
|---|---|---|
| -1,689.87 % | -30.12% | |
| -2,418.29 % | +7.15% | |
| -2,256.94 % | +45.87% | |
| -1,547.27 % | -821.38% | |
| 214.49 % | -131.80% | |
| -674.58 % | -20.46% | |
| -848.10 % | +463.98% | |
| -150.38 % | — |
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Infinity Pharmaceuticals Stock analysis
Frequently Asked Questions about Infinity Pharmaceuticals stock
Rule of 40 of Infinity Pharmaceuticals is -1,689.87 % in 2022.
On Eulerpool you can find the complete historical development of Rule of 40 Infinity Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.
The Rule of 40 states that a company's revenue growth rate plus profit margin should exceed 40%. It is widely used to evaluate SaaS and high-growth companies.
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Quality — Infinity Pharmaceuticals
All Key Metrics — Infinity Pharmaceuticals
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth